Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | ADH1B | P00325 | 1/20 | 0.43 |
| ▸ | ADH1C | P00326 | 1/20 | 0.43 |
| ▸ | ADH1A | P07327 | 1/20 | 0.43 |
| ▸ | ADH7 | P40394 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL460010 | 0.71 | PTPRF (0.47) | CYP3A4MAPTKDM4EIDO1THRB | |
| SCHEMBL745087 | 0.71 | IDO1 (0.50) | CYP3A4MAPTKDM4EIDO1THRB | |
| SCHEMBL24334039 | 0.70 | CYP3A4 (0.94) | CYP3A4MAPTKDM4EIDO1THRB | |
| N-Benzylmethylamine SCHEMBL2271 | 0.70 | — | — | |
| N-Benzylmethylamine SCHEMBL4609847 | 0.70 | CYP3A4 (0.94) | CYP3A4MAPTKDM4EIDO1THRB | |
| SCHEMBL5028089 | 0.70 | — | — | |
| N-Benzylmethylamine SCHEMBL11696446 | 0.70 | CYP3A4 (0.94) | CYP3A4MAPTKDM4EIDO1THRB | |
| N-Benzylmethylamine SCHEMBL29287388 | 0.70 | — | — | |
| Bromide SCHEMBL17187557 | 0.70 | PTPRF (0.46) | CYP3A4MAPTKDM4EIDO1THRB | |
| Hydrochloric Acid SCHEMBL6045117 | 0.70 | MAPT (0.46) | CYP3A4MAPTKDM4EIDO1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702401-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2023-07-18 | — | — | US | disclosed |
| US-11242345-B2 | Sulfonimidoylpurinone compounds and methods of treatment using the same | HOFFMANN-LA ROCHE INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20220000847-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC (US) | 2022-01-06 | — | — | US | disclosed |
| US-11053216-B2 | Compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2021-07-06 | — | — | US | disclosed |
| EP-3089971-B1 | COMPOUNDS AND METHODS OF USE | MEDIVATION TECH LLC (US) | 2020-07-29 | — | — | EP | disclosed |
| US-20200109144-A1 | Sulfonimidoylpurinone Compounds | HOFFMANN-LA ROCHE INC. (US) | 2020-04-09 | — | — | US | disclosed |
| US-20200071296-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2020-03-05 | — | — | US | disclosed |
| EP-3294740-B1 | NOVEL SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2019-09-04 | — | — | EP | disclosed |
| US-10399983-B2 | Sulfonimidoylpurinone compounds | HOFFMANN-LA ROCHE INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180208577-A1 | Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-07-26 | — | — | US | disclosed |
| US-20120135990-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120094917-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP (US) | 2012-04-19 | — | — | US | disclosed |
| EP-2434890-A1 | IAP INHIBITORS | Tetralogic Pharmaceuticals Corp. (US) | 2012-04-04 | — | — | EP | disclosed |
| EP-2434889-A1 | IAP INHIBITORS | Tetralogic Pharmaceuticals Corp. (US) | 2012-04-04 | — | — | EP | disclosed |
| US-20110237517-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. | 2011-09-29 | — | — | US | disclosed |
| WO-2011068926-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2011-06-09 | — | — | WO | disclosed |
| EP-2328412-A1 | IAP INHIBITORS | Tetralogic Pharmaceuticals Corp. (US) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010138496-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138666-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010033531-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. (US) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000847-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | CYP3A4 4780/4885MAPT 1108/4885KDM4E 1713/4885 |
| US-20110237517-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | CYP3A4 3818/4885MAPT 375/4885KDM4E 2828/4885 |
| US-11702401-B2 | Compounds and methods of use | TGFB2, TGFB1, HDGF | CYP3A4 4780/4885MAPT 1108/4885KDM4E 1713/4885 |
| US-20120135990-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | CYP3A4 3818/4885MAPT 375/4885KDM4E 2828/4885 |
| US-20200109144-A1 | Sulfonimidoylpurinone Compounds | NQO1, UGT1A1, SULT1E1 | CYP3A4 128/4885MAPT 3001/4885KDM4E 2226/4885 |
| US-10399983-B2 | Sulfonimidoylpurinone compounds | NQO1, UGT1A1, SULT1E1 | CYP3A4 128/4885MAPT 3001/4885KDM4E 2226/4885 |
| US-20200071296-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | CYP3A4 4780/4885MAPT 1108/4885KDM4E 1713/4885 |
| US-11053216-B2 | Compounds and methods of use | TGFB2, TGFB1, HDGF | CYP3A4 4780/4885MAPT 1108/4885KDM4E 1713/4885 |
| US-11242345-B2 | Sulfonimidoylpurinone compounds and methods of treatment using the same | STS, SULT1E1, SULT1A1 | CYP3A4 199/4885MAPT 3633/4885KDM4E 1661/4885 |
| US-20180208577-A1 | Compounds and Methods of Use | TGFB2, TGFB1, HDGF | CYP3A4 4780/4885MAPT 1108/4885KDM4E 1713/4885 |
| US-20120094917-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | CYP3A4 3818/4885MAPT 375/4885KDM4E 2828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.